Orion and Peptonic partner up for health
Finnish Orion and Swedish Peptonic Medical have announced a tech transfer agreement for VagiVital, a product set to be launched next year.
Under the agreement, the two companies promise to exchange information and collaborate to prepare for the commercial manufacture of VagiVital, a hormone-free self-care product for the treatment of vaginal atrophy and dryness. The product has been tested in randomised clinical studies with very positive results.
“We are very pleased to have partnered with a world class player like Orion for the manufacture of VagiVital,” says Johan Inborr, CEO of Peptonic. “The Orion collaboration gives to VagiVital the quality label that it deserves and to Peptonic the possibility for the development of additional products.”
Orion is a globally operating pharmaceutical company that develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests.